Video Archives - WuXi Biology

End-to-End CRDMO Platform for Oligonucleotide Drugs

Since the approval of the first siRNA drug in 2018, oligonucleotide therapeutics have rapidly emerged as a promising drug modality. ...

Key Steps in Validating Targeted Protein Degraders

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have...

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Targeted Protein Degraders: Trends, Challenges, and Solutions

Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs). Our platform enables research...

Poster Presentations at AACR 2025

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present...

Animal Disease Models of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a prevalent, chronic, autoimmune disease. The onset and progression of RA are closely associated with an...

Paclitaxel-Induced Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...

Radionuclide Drug Conjugates

Radiopharmaceuticals have proven to be effective agents since they can be successfully applied for both diagnostics and therapy. Radionuclide drug...

Combating Drug Resistance in Cancer Therapy

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to...

Knowledge Library